İstanbul Journal of Pharmacy

SUBMITINFORMATION
EnglishTürkçe

Review


DOI :10.5152/IstanbulJPharm.2017.0018   IUP :10.5152/IstanbulJPharm.2017.0018    Full Text (PDF)

Targeted drug delivery and vaccinology approaches using virus-like particles for cancer

Şeyma Şereflioğlu, Emine Yapıcı, Şeyma Hande Tekarslan Şahin, Yıldız Özsoy Erginer, Cem Bülent Üstündağ

Nanotechnology has the potential to make significant alterations in the treatment of diseases such as cancer through targeted drug delivery nanoparticles. Virus-like particles (VLPs) are composed of the capsid proteins that do not carry the viral genome and are also noninfectious. VLPs are self-assembling competent protein structures with identical or highly related structures to their corresponding native viruses. VLPs that have precise 3D nanostructures exhibit a notable diversity in shapes and structures. They can be produced in large quantities through biological amplification and growth. External protein inserts can be displayed through genetic methods or chemical modifications. Functionalized VLPs when used as delivery systems have the ability to target with specificity and can attract macrophages for the destruction of cancer cells. The capability to target tumors for the delivery of therapeutic agents is an important goal of the design approaches of VLPs. Against the current problems in cancer therapies, delivery systems using VLPs are an arising and promising field with the potential to exhibit solutions. Cancer therapies require specific targeting of the diagnostic element or the drug to tumor cells without binding to or affecting healthy cells and tissues. Specialization of the VLPs provides an opportunity for using them as site-specific drug delivery systems in cancer therapy while reducing the systemic toxicity and the overall damage to healthy cells. With fewer side effects, immunotherapy is also a promising alternative for cancer treatment by primarily activating the host’s immune system. Cancer vaccines are aimed at inducing an immune response in the host, thereby generating a defensive mechanism against tumor cells. VLPs can be used as a vaccine without the requirement of any adjuvant due to their naturally optimized particle size and their repetitive structural order. Therefore, the aim of this review is to provide basic information about VLPs and describe previous research on VLPs used as drug and vaccine delivery systems and their applications in different types of cancer.

Keywords: Nanocarriers, virus-like particles, drug delivery, cancer vaccine, cancer therapy

PDF View

References

  • Abbing A, Blaschke UK, Grein S, Kretschmar M, Stark CM, Thies MJ, Walter J, Weigand M, Woith DC, Hess J et al. (2004) Efficient intracellular delivery of a protein and a low molecular weight substance via recombinant polyo mavirus-like particles, J. Biol. Chem., 279:27410-27421. google scholar
  • Aljabali AA, Shukla S, Lomonossoff GP, Steinmetz NF, Evans DJ (2013) CPMV-DOX delivers, Mol. Pharm., 10:3-10. google scholar
  • Alpar HO, Özsoy Y, Cevher E (2014) Nanotaşıyıcıların Aşı Uygulamasında Kullanılması. In: Zırh-Gürsoy A (ed.) Nanofarmasötikler ve Uygulamaları, Kontrollü Salım Sistemler Derneği, İstanbul, pp.277-286. google scholar
  • Ashley CE, Carnes EC, Phillips GK, Durfee PN, Buley MD, Lino CA, Padilla DP, Phillips B, Carter MB, Willman CL et al. (2011) Cell-specific delivery of diverse cargos by bacteriophage MS2 virus-like particles, ACS Nano, 5:5729-5745. google scholar
  • Blokhina EA, Kupriyanov VV, Ravin NV, Skryabin KG (2013) The Method of Noncovalent in vitro Binding of Target Proteins to Virus-Like Nanoparticles Formed by Core Antigen of Hepatitis B Virus, Dokl. Akad. Nauk., 448: 719–721. google scholar
  • Choi KM, Kim K, Kwon IC, Kim IS, Ahn HJ (2013) Systemic delivery of siRNA by chimeric capsid protein: tumor targeting and RNAi activity in vivo, Mol. Pharm., 10:18-25. google scholar
  • Chou MI, Hsieh YF, Wang M, Chang JT, Chang D, Zouali M, Tsay GJ (2010) In vitro and in vivo targeted delivery of IL-10 interfering RNA by JC virus-like particles, J. Biomed. Sci., 17:51. google scholar
  • Dillner J, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G, Brown DR, Koutsky LA, Tay EH, García P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Lehtinen M, Steben M, Bosch FX, Joura EA, Majewski S, Muñoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan JT, Maansson R, Lu S, Vuocolo S, Hesley TM, Barr E, Haupt R. (2010) Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ., 341:c3493. google scholar
  • Deo VK, Kato T, Park EY (2015) Chimeric Virus-Like Particles Made Using GAG and M1 Capsid Proteins Providing Dual Drug Delivery and Vaccination Platform, Mol. Pharm., 12:839−845. google scholar
  • Fua Y, Li J (2016) A novel delivery platform based on Bacteriophage MS2 virus-like particles, Virus Res., 211:9–16. Galaway FA, Stockley PG (2013) MS2 viruslike particles: a robust, semisynthetic targeted drug delivery platform, Mol. Pharm., 10:59-68. google scholar
  • Glaxosmithkline Vaccine HPVSG, Romanowski B, De Borba PC, Naud PS, Roteli-Martins CM, De Carvalho NS, Teixeira JC, Aoki F, Ramjattan B, Shier RM, Somani R, Barbier S, Blatter MM, Chambers C, Ferris D, Gall SA, Guerra FA, Harper DM, Hedrick JA, Henry DC, Korn AP, Kroll R,Moscicki AB, Rosenfeld WD, Sullivan BJ, Thoming CS, Tyring SK, Wheeler CM, Dubin G, Schuind A, Zahaf T, Greenacre M, Sgriobhadair A (2009) Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet., 374(9706):1975–1985. google scholar
  • Ghasparian A, Riedel T, Koomullil J, Moehle K, Gorba C, Svergun DI, Perriman AW, Mann S, Tamborrini M, Pluschke G, Robinson JA (2011) Engineered Synthetic Virus-Like Particles and Their Use in Vaccine Delivery, ChemBioChem, 12:100 – 109. google scholar
  • Goldinger SM, Imhof L, Willers J, French LE, Dummer R, (2010) Phase II clinical trial using Virus-Like Particle (VLP) vaccine including a melan-A analogon and imiquimod”, Melanoma Res., 20:e56. google scholar
  • Grgacic EV, Anderson DA (2006) Virus-like particles: Passport to immune recognition, Methods, 40:60– 65. google scholar
  • Hauser P, Voet P, Simoen E (1987) Immunological properties of recombinant HbsAg produced in yeast. Postgrad Med J., 63:83–91. google scholar
  • Hourvitz A1, Mosseri R, Solomon A, Yehezkelli Y, Atsmon J, Danon YL, Koren R, Shouval D (1996) Reactogenicity and immunogenicity of a new recombinant hepatitis B vaccine containing Pre S antigens: a preliminary report. J Viral Hepat.,3(1):37-42. google scholar
  • Huang X, Wang X, Jun Zhang J, Xia N, Zhao Q (2017) Escherichia coli-derived virus-like particles in vaccine development. Vaccines, doi:10.1038/s41541-017-0006-8. google scholar
  • Kaczmarczyk SJ, Sitaraman K, Young HA, Hughes SH, Chatterjee DK (2011) Protein delivery using engineered virus-like particles, Proc. Natl. Acad. Sci., 108:16998-17003. google scholar
  • Kapusta J, Modelska A, Figlerowicz M, Pniewski T, Letellier M, Lisowa O, Yusibov V, Koprowski H, Plucienniczak A, Legocki AB. (1999)A plant-derived edible vaccine against hepatitis B virus. FASEB J., 13(13):1796-9. google scholar
  • Kaufmann AM, Nitschmann S (2010) Vaccine against human papillomavirus: PATRICIA Study (PApilloma TRIal against Cancer In young Adults). Der Internist., 51(3):412–413. google scholar
  • Kreimer AR, Gonzalez P, Katki HA, Porras C, Schiffman M, Rodriguez AC, Solomon D, Jiménez S, Schiller JT, Lowy DR, van Doorn LJ, Struijk L, Quint W, Chen S, Wacholder S, Hildesheim A, Herrero R; CVT Vaccine Group. (2011) Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. The lancet oncology., 12(9):862–870. google scholar
  • Kyriakopoulos S, Kontoravdi C (2013) Analysis of the landscape of biologicallyderived pharmaceuticals in Europe: dominant production systems, molecule types on the rise and approval trends. Eur. J. Pharm. Sci., 48: 428–441. google scholar
  • Kushnir N, Streatfield SJ, Yusibov V (2012) Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development. Vaccine., 31(1):58-83. google scholar
  • Lacson E, Teng M, Ong J, Vienneau L, Ofsthun N, Lazarus JM (2005) Antibody response to Engerix-B and Recombivax-HB hepatitis B vaccination in end-stage renal disease. Hemodial Int., 9(4):367-75. google scholar
  • Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, Castellsagué X, Skinner SR, Apter D, Naud P, Salmerón J, Chow SN, Kitchener H, Teixeira JC, Hedrick J, Limson G, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, De Carvalho NS, Germar MJ, Peters K, Mindel A, De Sutter P, Bosch FX, David MP, Descamps D, Struyf F, Dubin G; HPV PATRICIA Study Group. (2012) Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. The lancet oncology., 13(1):89–99. google scholar
  • Li SW, Zhao Q, Wu T, Chen S, Zhang J, Xia NS. (2015) The development of a recombinant hepatitis E vaccine HEV 239. Hum. vaccin immunother., 11: 908–914. google scholar
  • Lobaina Y, Aguiar J, Pentón E , Aguilar JC (2015) Demonstration of safety, immunogenicity and evidences of efficacy of the therapeutic vaccine candidate HeberNasvac and characterization of chronic hepatitis B patient populations. Biotecnología Aplicada., 32: 3511–3513. google scholar
  • Lockney DM, Guenther RN, Loo L, Overton W, Antonelli R, Clark J, Hu M, Luft C, Lommel SA, Franzen S (2011) The Red clover necrotic mosaic virus capsid as a multifunctional cell targeting plant viral nanoparticle, Bioconjug. Chem., 22:67-73. Lua LH, Connors NK, Sainsbury F, Chuan YP, Wibowo N, Middelberg AP (2014) Bioengineering virus-like particles as vaccines. Biotechnol. Bioeng., 111: 425–440. google scholar
  • Ma Y et al. (2012) Virus-based nanocarriers for drug delivery, Adv. Drug Deliv. Rev., 64:811–825. google scholar
  • Mao C, Koutsky LA, Ault KA, Wheeler CM, Brown DR, Wiley DJ, Alvarez FB, Bautista OM, Jansen KU, Barr E. (2006) Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstetrics and gynecology., 107(1):18–27. Manzenrieder F, Luxenhofer R, Retzlaff M, Jordan R, Finn MG, (2011) Stabilization of Virus-like Particles with Poly(2-oxazoline)s, Angew. Chem. Int. Ed., 50:2601 –2605. google scholar
  • Matassov D, Cupo A, Galarza JM, (2007) A Novel Intranasal Virus-Like Particle (VLP) Vaccine Designed to Protect against the Pandemic 1918 Influenza A Virus (H1N1), Viral Immunol., 20(3):441-52. google scholar
  • Molino NM, Wang S (2014) Caged protein nanoparticles for drug delivery, Curr. Opi. Biotechnol., 28:75–82. google scholar
  • Niikura K, Sugimura N, Musashi Y, Mikuni S, Matsuo Y, Kobayashi S, Nagakawa K, Takahara S, Takeuchi C, Sawa H et al. (2013) Virus-like particles with removable cyclodextrins enable glutathionetriggered drug release in cells, Mol. Biosyst., 9:501-507. google scholar
  • Parkin, DM, (2006) The global health burden of infection-associated cancers in the year 2002, Int. J. Cancer, 118: 3030–3044. google scholar
  • Proffitt A (2012) First HEV vaccine approved. Nature Biotechnology, doi:10.1038/nbt0412-300a. google scholar
  • Ren Y, Wong SM, Lim LY (2007) Folic acid-conjugated protein cages of a plant virus: a novel delivery platform for doxorubicin, Bioconjug. Chem., 18:836-843. google scholar
  • Rosenthal et al. (2014) Pathogen-like particle vaccines: biomimetic vaccine carriers engineered at the nanoscale, Curr. Opi. Biotechnol., 28:51–58. google scholar
  • Schiller JT, Castellsague X, Garland SM (2012) A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine, 30: F123–F138. google scholar
  • Shan L, Cui S, Du C, Wan S, Qian Z, Achilefu S, Gu Y (2012) A paclitaxel- conjugated adenovirus vector for targeted drug delivery for tumor therapy, Biomater., 33:146-162. google scholar
  • Shen L, Zhou J, Wang Y, Kang N, Ke X, Bi S, Ren L (2015) Efficient Encapsulation of Fe3O4 Nanoparticles into Genetically Engineered Hepatitis B Core Virus-Like Particles Through a Specific Interaction for Potential Bioapplications, Small Journal, Wiley-VCH GmbH & Co. google scholar
  • Shirbaghaee Z, Bolhassani A, (2016) Different Applications of Virus-Like Particles in Biology and Medicine: Vaccination and Delivery Systems, Biopolym., 105:113-132. google scholar
  • Smith JD, Morton LD, Ulery BD (2015) Nanoparticles as synthetic vaccines, Curr. Opin. Biotechnol., 34:217–224. google scholar
  • Teunissen EA, Raad M, Mastrobattista E (2013) Production and biomedical applications of virus-like particles derived from polyomaviruses, J. Control. Release, 172: 305–321. google scholar
  • Venters C, Graham W, Cassidy W (2004) Recombivax-HB: perspectives past, present and future. Expert Rev. Vaccines., 3, 119–129. google scholar
  • Wei M, Zhang X, Yu H, Tang ZM, Wang K, Li Z, Zheng Z, Li S, Zhang J, Xia N, Zhao Q (2014) Bacteria expressed hepatitis E virus capsid proteins maintain virionlike epitopes. Vaccine, 32: 2859–2865. google scholar
  • West DJ, Calandra GB (1996) Vaccine induced immunologic memory for hepatitis B surface antigen: Implications for policy on booster vaccination. Vaccine., 14:1019– 1027. google scholar
  • Yildiz I, Shukla S, Steinmetz NF, (2011) Applications of viral nanoparticles in medicine, Curr. Opi. Biotechnol., 22:901–908. google scholar
  • Zeng Q, Wen H, Wen Q, Chen X, Wang Y, Xuan W, Liang J, Wan S (2013) Cucumber mosaic virus as drug delivery vehicle for doxorubicin, Biomater., 34:4632-4642. google scholar
  • Zhao Q, Li S, Yu H, Xia N, Modis Y (2013) Virus-like particle-based human vaccines: quality assessment based on structural and functional properties, Trends Biotechnol., 31(11):654-63. google scholar
  • Zhao L, Setha A, Wibowo N, Zhao CX, Mitter N, Yu C, Middelberg A (2014) Nanoparticle vaccines, Vaccine, 32:327– 337. google scholar
  • Zhao Q, Potter CS, Carragher B, Lander G, Sworen J, Towne V, Abraham D, Duncan P, Washabaugh MW, Sitrin RD (2014) Characterization of virus-like particles in GARDASIL® by cryo transmission electron microscopy, Hum. Vaccines & Immunother., 10:3, 734–739. google scholar
  • Zhou Z, Bedwell GJ, Li R, Prevelige PE, Gupta JA (2014) Formation mechanism of chalcogenide nanocrystals confined inside genetically engineered virus-like particles, Sci. Rep., 4:3832. google scholar
  • Zochowska M, Paca A, Schoehn G, Andrieu JP, Chroboczek J, Dublet B, Szolajska E (2009) Adenovirus dodecahedron, as a drug delivery vector, PLoS One, 4:e5569. google scholar
  • zur Hausen, H, (2001) Viruses in human cancers, Curr. Sci., 81:523–527. google scholar
  • (2015) ABX203 (HeberNasvac) granted cuban marketing authorization to treat chronic Hepatitis B. Available at: http://www.abivax.com/images/pdf/ 151208_ABX203_Cuban_Authorization.pdf Accessed 29.03.2017. google scholar

Citations

Copy and paste a formatted citation or use one of the options to export in your chosen format


EXPORT



APA

Şereflioğlu, Ş., Yapıcı, E., Tekarslan Şahin, Ş., Özsoy Erginer, Y., & Üstündağ, C. (2017). Targeted drug delivery and vaccinology approaches using virus-like particles for cancer. İstanbul Journal of Pharmacy, 47(3), 112-119. https://doi.org/10.5152/IstanbulJPharm.2017.0018


AMA

Şereflioğlu Ş, Yapıcı E, Tekarslan Şahin Ş, Özsoy Erginer Y, Üstündağ C. Targeted drug delivery and vaccinology approaches using virus-like particles for cancer. İstanbul Journal of Pharmacy. 2017;47(3):112-119. https://doi.org/10.5152/IstanbulJPharm.2017.0018


ABNT

Şereflioğlu, Ş.; Yapıcı, E.; Tekarslan Şahin, Ş.; Özsoy Erginer, Y.; Üstündağ, C. Targeted drug delivery and vaccinology approaches using virus-like particles for cancer. İstanbul Journal of Pharmacy, [Publisher Location], v. 47, n. 3, p. 112-119, 2017.


Chicago: Author-Date Style

Şereflioğlu, Şeyma, and Emine Yapıcı and Şeyma Hande Tekarslan Şahin and Yıldız Özsoy Erginer and Cem Bülent Üstündağ. 2017. “Targeted drug delivery and vaccinology approaches using virus-like particles for cancer.” İstanbul Journal of Pharmacy 47, no. 3: 112-119. https://doi.org/10.5152/IstanbulJPharm.2017.0018


Chicago: Humanities Style

Şereflioğlu, Şeyma, and Emine Yapıcı and Şeyma Hande Tekarslan Şahin and Yıldız Özsoy Erginer and Cem Bülent Üstündağ. “Targeted drug delivery and vaccinology approaches using virus-like particles for cancer.” İstanbul Journal of Pharmacy 47, no. 3 (Apr. 2025): 112-119. https://doi.org/10.5152/IstanbulJPharm.2017.0018


Harvard: Australian Style

Şereflioğlu, Ş & Yapıcı, E & Tekarslan Şahin, Ş & Özsoy Erginer, Y & Üstündağ, C 2017, 'Targeted drug delivery and vaccinology approaches using virus-like particles for cancer', İstanbul Journal of Pharmacy, vol. 47, no. 3, pp. 112-119, viewed 25 Apr. 2025, https://doi.org/10.5152/IstanbulJPharm.2017.0018


Harvard: Author-Date Style

Şereflioğlu, Ş. and Yapıcı, E. and Tekarslan Şahin, Ş. and Özsoy Erginer, Y. and Üstündağ, C. (2017) ‘Targeted drug delivery and vaccinology approaches using virus-like particles for cancer’, İstanbul Journal of Pharmacy, 47(3), pp. 112-119. https://doi.org/10.5152/IstanbulJPharm.2017.0018 (25 Apr. 2025).


MLA

Şereflioğlu, Şeyma, and Emine Yapıcı and Şeyma Hande Tekarslan Şahin and Yıldız Özsoy Erginer and Cem Bülent Üstündağ. “Targeted drug delivery and vaccinology approaches using virus-like particles for cancer.” İstanbul Journal of Pharmacy, vol. 47, no. 3, 2017, pp. 112-119. [Database Container], https://doi.org/10.5152/IstanbulJPharm.2017.0018


Vancouver

Şereflioğlu Ş, Yapıcı E, Tekarslan Şahin Ş, Özsoy Erginer Y, Üstündağ C. Targeted drug delivery and vaccinology approaches using virus-like particles for cancer. İstanbul Journal of Pharmacy [Internet]. 25 Apr. 2025 [cited 25 Apr. 2025];47(3):112-119. Available from: https://doi.org/10.5152/IstanbulJPharm.2017.0018 doi: 10.5152/IstanbulJPharm.2017.0018


ISNAD

Şereflioğlu, Şeyma - Yapıcı, Emine - Tekarslan Şahin, Şeyma Hande - Özsoy Erginer, Yıldız - Üstündağ, Cem Bülent. “Targeted drug delivery and vaccinology approaches using virus-like particles for cancer”. İstanbul Journal of Pharmacy 47/3 (Apr. 2025): 112-119. https://doi.org/10.5152/IstanbulJPharm.2017.0018



TIMELINE


Accepted06.11.2017

LICENCE


Attribution-NonCommercial (CC BY-NC)

This license lets others remix, tweak, and build upon your work non-commercially, and although their new works must also acknowledge you and be non-commercial, they don’t have to license their derivative works on the same terms.


SHARE




Istanbul University Press aims to contribute to the dissemination of ever growing scientific knowledge through publication of high quality scientific journals and books in accordance with the international publishing standards and ethics. Istanbul University Press follows an open access, non-commercial, scholarly publishing.